cabergoline has been researched along with Cirrhosis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Albarel, F; Amodru, V; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Graillon, T; Morange, I | 1 |
| Chia, YY; Goh, GH; Mohan, N; Teo, K; Ting, E; Yeo, TT | 1 |
| Ariano, C; De Vecchis, R; Esposito, C | 1 |
| Andersohn, F; Garbe, E | 1 |
| Bridgman, P; Cawood, TJ; Cole, D; Hunter, L | 1 |
| Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH | 1 |
| Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM | 1 |
| Bötzel, K; Levin, J; Näbauer, M; Neudert, J; Zwermann, L | 1 |
| Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S | 1 |
| MacIver, DH; Townsend, M | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Luce, P; Medcalf, P; Odin, P; Stegie, F | 1 |
| Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH | 1 |
3 review(s) available for cabergoline and Cirrhosis
| Article | Year |
|---|---|
The risks of medical treatment of prolactinoma.
Topics: Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Heart Valve Diseases; Humans; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Substance-Related Disorders | 2021 |
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Myocardium; Observational Studies as Topic; Prevalence; Risk Factors | 2013 |
Drug-induced fibrotic valvular heart disease.
Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents | 2009 |
1 trial(s) available for cabergoline and Cirrhosis
| Article | Year |
|---|---|
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency | 2007 |
9 other study(ies) available for cabergoline and Cirrhosis
| Article | Year |
|---|---|
Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
Topics: Adult; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Ergolines; Fibrosis; Humans; Hypogonadism; Hypothyroidism; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Thyroxine; Tricuspid Valve Insufficiency | 2017 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Topics: Brain Ischemia; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fatal Outcome; Fibrosis; Heart Valve Prosthesis Implantation; Humans; Intestinal Obstruction; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left | 2009 |
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric | 2010 |
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Echocardiography, Doppler, Color; Ergolines; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Parkinson Disease | 2011 |
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies | 2012 |
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Ergolines; Fibrosis; Humans; Male; Middle Aged; Parkinson Disease; Pericarditis, Constrictive; Pleura; Pulmonary Fibrosis | 2004 |
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2004 |
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Retrospective Studies | 2005 |